 The prognostic value and the best method of testing of topoisomerase II alpha ( TOP2A) status have not been established in modern tailored therapy based on breast cancer subtype. The frequencies of TOP2A overexpression and In modern tailored therapy , TOP2A overexpression can be a poor prognostic factor in luminal B breast cancer. In contrast , Between May 2005 and April 2015 , a total of 643 consecutive non-metastatic invasive breast cancers were evaluated for